NCT07539090 Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
| NCT ID | NCT07539090 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Deciphera Pharmaceuticals, LLC |
| Condition | Healthy Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-06-05 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2026-06-05 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.
Eligibility Criteria
Inclusion Criteria: 1. Participants are in good general health, as required by the protocol and as determined by Principal Investigator. 2. Body mass index (BMI) from greater than or equal to (≥) 18.5 to less than or equal to ≤ 30 kilogram per square meter (kg/m\^2). 3. Adequate organ function, blood and urine tests, as required by the protocol and as determined by Principal Investigator. Exclusion Criteria: 1. History or presence of clinically significant diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease as determined by Principal Investigator. 2. Unwilling or unable to comply with the requirements of the protocol. 3. Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.
Contact & Investigator
Clinical Team
STUDY DIRECTOR
Deciphera Pharmaceuticals, LLC
Frequently Asked Questions
Who can join the NCT07539090 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 55 Years, studying Healthy Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07539090 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07539090 currently recruiting?
Yes, NCT07539090 is actively recruiting participants. Contact the research team at clinicaltrials@deciphera.com for enrollment information.
Where is the NCT07539090 trial being conducted?
This trial is being conducted at Saint Paul, United States.
Who is sponsoring the NCT07539090 clinical trial?
NCT07539090 is sponsored by Deciphera Pharmaceuticals, LLC. The principal investigator is Clinical Team at Deciphera Pharmaceuticals, LLC. The trial plans to enroll 24 participants.